| Drug Name |
Vancomycin |
| Drug ID |
BADD_D02332 |
| Description |
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of _Clostridium difficile_ associated diarrhea and enterocolitis caused by _Staphylococcus aureus_, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make _Clostridium difficile_ associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196]. |
| Indications and Usage |
Additionally, a unique FDA approved oral liquid treatment is also available and indicated for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by _Staphylococcus aureus_, including methicillin-resistant strains [L1196]. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
A07AA09; J01XA01; S01AA28 |
| DrugBank ID |
DB00512
|
| KEGG ID |
D00212
|
| MeSH ID |
D014640
|
| PubChem ID |
14969
|
| TTD Drug ID |
D0B1IV
|
| NDC Product Code |
45932-0050; 65628-200; 65628-201; 70594-043; 68001-338; 70594-058; 52946-0836; 70594-056; 70594-040; 68001-339; 70594-057; 70594-041; 70594-044; 70594-042 |
| Synonyms |
Vancomycin | Vancomycin Hydrochloride | Hydrochloride, Vancomycin | Vancomycin Sulfate | Sulfate, Vancomycin | Vancomycin-ratiopharm | Vancomycin Hexal | Vancomycine Dakota | AB-Vancomycin | Vanco Azupharma | Diatracin | VANCO-cell | Vanco-saar | Vancocin | Vancocin HCl | Vancomycin Lilly | Vancocine | Vancomicina Abbott | Vancomicina Chiesi | Vancomicina Combino Phar | Vancomicina Norman | Vancomycin Phosphate (1:2) | Vancomycin Phosphate (1:2), Decahydrate |
